| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 300-600 from human PLA2R1 protein was used as the immunogen for the Phospholipase A2 Receptor 1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Phospholipase A2 Receptor 1 Antibody / PLA2R1 is an antibody targeting Phospholipase. Host: Mouse. Monoclonal. Clone: PLA2R1/4897. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: Phospholipase.
- Immunogen: A portion of amino acids 300-600 from human PLA2R1 protein was used as the immunogen for the Phospholipase A2 Receptor….
- Species reactivity: Human.
- Localization: Cell membrane, Secreted.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Phospholipase A2 Receptor 1 may play a role in clearance of phospholipase A2, thereby inhibiting its action.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
